Durability Data, New Treatment Option Prompt ASCO to Update Living Guideline on Stage IV NSCLC Without Driver Alterations
Abstract
ASCO has updated its living guideline on treatment of patients with stage IV NSCLC without driver alterations based on newly available long-term follow-up data from key trials as well as demonstrated activity and approval of telisotuzumab vedotin for previously treated patients.
Fields of Study & Subjects
Lung Cancer Treatments and Mutations
Lung Cancer Diagnosis and Treatment
Lung Cancer Research Studies
Publication details
- Journal / source
- Default Digital Object Group
- Publication date
- 3 February 2026
- Document type
- Dataset